NASDAQ:SAGE Sage Therapeutics - SAGE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $44.97 +0.46 (+1.03%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$43.40▼$45.1650-Day Range$35.05▼$45.5852-Week Range$27.36▼$49.56Volume384,752 shsAverage Volume445,285 shsMarket Capitalization$2.68 billionP/E RatioN/ADividend YieldN/APrice Target$48.29 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sage Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside7.4% Upside$48.29 Price TargetShort InterestHealthy7.52% of Float Sold ShortDividend StrengthN/ASustainability-1.37Upright™ Environmental ScoreNews Sentiment0.21Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.90) to ($8.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector862nd out of 1,048 stocksPharmaceutical Preparations Industry428th out of 513 stocks 2.1 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.29, Sage Therapeutics has a forecasted upside of 7.4% from its current price of $44.97.Amount of Analyst CoverageSage Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.52% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Sage Therapeutics has recently decreased by 8.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 72.37% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.37. Previous Next 2.3 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Sage Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for SAGE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions85.60% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($8.90) to ($8.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sage Therapeutics (NASDAQ:SAGE) StockSAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.Read More Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comFY2023 Earnings Estimate for Sage Therapeutics, Inc. Issued By SVB Leerink (NASDAQ:SAGE)January 24, 2023 | marketwatch.comEssential Tremor Treatment Market Register to Growth by 2023-2027 | Global Revenue and Key Dynamics with Industry SegmentsJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 23, 2023 | americanbankingnews.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from AnalystsJanuary 13, 2023 | marketwatch.comEssential Tremor Treatment Market | Rising Sales of the Industry Are Set To Drive for Growth Prospects and InnovationsJanuary 10, 2023 | msn.comSage Therapeutics sees depression treatment zuranolone hitting the market as early as Q3January 10, 2023 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Stock Historical Prices & Data - Yahoo FinanceJanuary 8, 2023 | wsj.comSage Therapeutics to Provide Update on 2023 Key Initiatives at 41(st) Annual J.P. Morgan Healthcare ConferenceJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 7, 2023 | forbes.comSage TherapeuticsJanuary 7, 2023 | finance.yahoo.comSage Therapeutics (NASDAQ:SAGE) shareholders are up 5.6% this past week, but still in the red over the last five yearsJanuary 3, 2023 | finance.yahoo.comSage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023December 13, 2022 | seekingalpha.comSage Therapeutics Could Be In For A Depressing FDA ReviewDecember 10, 2022 | seekingalpha.comSage Therapeutics: Zuranolone NDA Near-Term TailwindDecember 7, 2022 | finance.yahoo.comBiogen (BIIB), Sage Finish Zuranolone NDA Filing for DepressionDecember 7, 2022 | finance.yahoo.comAn Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 31% UndervaluedDecember 6, 2022 | markets.businessinsider.comMizuho Securities Keeps Their Hold Rating on SAGE Therapeutics (SAGE)December 6, 2022 | finance.yahoo.com3 Biotech Stocks Aiming to Reinvent Mental Health TreatmentDecember 6, 2022 | finance.yahoo.comSage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionDecember 5, 2022 | msn.comSage Therapeutics's Return On Capital Employed InsightsNovember 23, 2022 | finance.yahoo.comSage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 22, 2022 | finance.yahoo.comSage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for ZuranoloneNovember 17, 2022 | finance.yahoo.comPresident Barry Greene Just Bought 45% More Shares In Sage Therapeutics, Inc. (NASDAQ:SAGE)November 16, 2022 | benzinga.comSage Therapeutics Recent Insider ActivityNovember 14, 2022 | finanznachrichten.deFinancialnewsmedia.com: Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug CandidatesNovember 14, 2022 | bizjournals.comWhat to know about Biogen's new CEONovember 11, 2022 | bizjournals.comHere are three things to know about Biogen's new CEOSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Company Calendar Last Earnings11/08/2022Today1/27/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees471Year FoundedN/APrice Target and Rating Average Stock Price Forecast$48.29 High Stock Price Forecast$73.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+7.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($8.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-457,890,000.00 Net Margins-7,895.27% Pretax Margin-7,895.27% Return on Equity-32.76% Return on Assets-30.84% Debt Debt-to-Equity RatioN/A Current Ratio14.70 Quick Ratio14.70 Sales & Book Value Annual Sales$6.31 million Price / Sales423.97 Cash FlowN/A Price / Cash FlowN/A Book Value$29.35 per share Price / Book1.53Miscellaneous Outstanding Shares59,490,000Free Float56,638,000Market Cap$2.68 billion OptionableOptionable Beta1.17 Key ExecutivesBarry E. GreenePresident, Chief Executive Officer & DirectorKimi E. IguchiChief Financial OfficerAl RobichaudChief Scientific OfficerAmy SchacterleSenior VP-Research & Development StrategyMatt LasmanisChief Technology & Innovation OfficerKey CompetitorsProthenaNASDAQ:PRTARevance TherapeuticsNASDAQ:RVNCAmylyx PharmaceuticalsNASDAQ:AMLXMyovant SciencesNYSE:MYOVIVERIC bioNASDAQ:ISEEView All CompetitorsInsiders & InstitutionsInspire Investing LLCBought 848 shares on 1/26/2023Ownership: 0.011%Pinnacle Associates Ltd.Bought 10,205 shares on 1/25/2023Ownership: 0.301%Baillie Gifford & Co.Bought 3,490 shares on 1/24/2023Ownership: 0.159%Allspring Global Investments Holdings LLCSold 9,961 shares on 1/23/2023Ownership: 0.147%Pendal Group LtdBought 8,702 shares on 1/19/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions SAGE Stock - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price forecast for 2023? 12 brokers have issued 1 year price targets for Sage Therapeutics' shares. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they anticipate the company's share price to reach $48.29 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2023? Sage Therapeutics' stock was trading at $38.14 at the beginning of 2023. Since then, SAGE stock has increased by 17.9% and is now trading at $44.97. View the best growth stocks for 2023 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our SAGE earnings forecast. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($2.31) EPS for the quarter, missing the consensus estimate of ($2.16) by $0.15. The biopharmaceutical company had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.68 million. Sage Therapeutics had a negative net margin of 7,895.27% and a negative trailing twelve-month return on equity of 32.76%. What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). What is Sage Therapeutics' stock symbol? Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE." Who are Sage Therapeutics' major shareholders? Sage Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.30%), Baillie Gifford & Co. (0.16%), Allspring Global Investments Holdings LLC (0.15%), Hennion & Walsh Asset Management Inc. (0.12%), Pendal Group Ltd (0.01%) and Inspire Investing LLC (0.01%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski and James M Frates. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sage Therapeutics' stock price today? One share of SAGE stock can currently be purchased for approximately $44.97. How much money does Sage Therapeutics make? Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.68 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.63) on an earnings per share basis. How many employees does Sage Therapeutics have? The company employs 471 workers across the globe. How can I contact Sage Therapeutics? Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379. This page (NASDAQ:SAGE) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.